Emerging therapeutics based on gene addition, editing, or silencing are expected to change the landscape of genetic liver disease.

Watch this episode to find out:

  • Which approaches exist?
  • Where are they in terms of preclinical and clinical development?
  • How will they be used?


  • Dr Mattias Mandorfer (Moderator)
  • Dr Gloria Gonzalez-Aseguinolaza (Faculty)
  • Prof. Pavel Strnad (Faculty)
  • Prof. Man-Fung Yuen (Faculty)

ℹ️ Please click here to access the podcast version of this EASL Studio episode.


Log in to post comments